One versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer

The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients with cancer are unknown. Interim analysis of a prospective observational study in three hospitals in London (UK) found that in patients with cancer, one dose of the Pfizer-BioNTech vaccine BNT162b2 yielded poor efficacy. Immunogenicity increased significantly in patients with solid cancer within two weeks of a vaccine boost at day 21 after the first dose. The authors conclude that these data support prioritisation of patients with cancer for an early (day 21) second dose of the BNT162b2 vaccine.